Gene Therapy Lyfgenia denied as not FDA-approved for this use by State Medicaid (varies)?

State Medicaid (varies)'s specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why State Medicaid Programs Issue "Not FDA-Approved" Denials for Lyfgenia

A "not FDA-approved" denial is a clear factual error when applied to Lyfgenia. Lyfgenia received full FDA approval and is not an investigational, compassionate-use, or off-label therapy when used for its approved indication. This type of denial most commonly results from a coverage database that has not been updated since FDA approval, a prior-authorization system that does not yet have the product coded, or a claims processing error that failed to recognize the correct product identifier.

This category of denial is among the most directly reversible, because the factual predicate — that the drug lacks FDA approval — is demonstrably wrong and can be disproven with publicly available federal regulatory documentation.

## Why This Denial Is Appealable

FDA approval is a matter of public federal record. No state Medicaid program or managed care plan can deny coverage of an FDA-approved product on the grounds that it lacks FDA approval when it does not. Providing the FDA approval letter and prescribing label as attachments to an appeal letter typically resolves this denial at the internal level. If it does not, an external reviewer will correct it.

## Your Appeal Rights and Timeline

• Immediate internal appeal or re-submission: Because this is a factual error, consider first calling the plan's provider services line with the FDA National Drug Code (NDC) and approval date to request a correction before filing a formal appeal. Document the call.
• Formal internal appeal: File within the deadline on the denial notice. Attach the FDA label and approval documentation.
• State Medicaid fair hearing: If the internal appeal is denied despite the FDA approval evidence, request a fair hearing. Bring the FDA documentation to the hearing.
• External review: Available through most Medicaid managed care plans for final adverse decisions. An independent reviewer will readily recognize that the "not approved" basis is factually incorrect.
• Expedited process: If the patient's clinical condition is time-sensitive, request expedited review at every level.

## Documentation to Gather

1. FDA prescribing label: Download directly from the FDA website (Drugs@FDA) and attach to every level of appeal. 2. FDA approval letter: The official FDA approval correspondence, also available on the FDA website. 3. Prescription and clinical records: The prescriber's order confirming the drug is being used for its FDA-approved indication, along with the diagnosis records confirming the qualifying sickle cell disease genotype. 4. NDC and product codes: Confirm the correct National Drug Code and J-code with the specialty pharmacy to ensure the claim was submitted with the correct product identifier — a coding error can generate this type of denial even when the insurer's database is current.

## Criteria-Mapping Structure

This appeal is simpler than most — the primary task is establishing the single controlling fact:

| Denial Basis | Rebuttal Evidence | |---|---| | Drug is not FDA approved | FDA approval letter (attached) + prescribing label (attached) | | Use is investigational | Prescriber letter confirming on-label use for approved indication | | Claim coding error | Corrected NDC + J-code from specialty pharmacy |

Keep the appeal letter concise and direct: state the factual error, attach the federal regulatory documentation, and request immediate reversal. Avoid introducing complexity that could distract from the straightforward factual basis for reversal.